- Revenue grew 37% year-on-year to INR 2,118 million in Q1 FY25
- EBITDA increased 30% year-on-year to INR 537 million
- Profit after tax grew 60% year-on-year to INR 304 million
- Overall occupancy improved to 61% compared to 51% in Q1 last year
- ARPOB (Average Revenue Per Occupied Bed) increased 9% to INR 30,551
- Noida Extension Hospital registered 81% Y-o-Y revenue growth, contributing 38% to topline
- Oncology now contributes 10% to group revenues and 17% for Noida Extension Hospital
- Government business contributes around 37% of revenues, down from 40% last year
Recovered INR 80 crores out of INR 227 crores outstanding receivables as of March 2024 - Debtor days reduced by around 5 days compared to last fiscal year end
- Targeting to bring debtor days close to 100 by end of current fiscal year
- Acquired 200-bed Faridabad Hospital which commenced operations in May 2024
- Planning to add 250 beds in Noida Extension and 200 beds in Greater Noida in next 2-3 years
- Signed NDA with a leading big six auditing firm for management audit and process improvements
- Focusing on expanding footprint across North India through organic and inorganic growth
- Targeting one inorganic acquisition per year
- Added robotic surgery capabilities including Da Vinci, MAKO and Cuvis robots
- Planning to start medical and surgical oncology and cardiac surgery in Jhansi hospital
- Targeting to reach 2,800-3,000 beds by FY28 from current 1,605 beds
- Expecting to reach close to INR 1,000 crores revenue in FY25
- Targeting sustainable EBITDA margin of around 25% at consolidated level
- Faridabad hospital expected to break-even in 18 months and reach 20%+ EBITDA margin in 3 years
| Subscribe To Our Free Newsletter |
